Vous êtes ici

2017

2017

1- Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376:209-220.               IF2017 = 79,260; 5YIF = 67,513

2-de Seze J. MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease? Brain. 2017;140:3072-3075. IF2017 = 10,848; 5YIF = 11,202

3- Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Seze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. Ann Neurol2017;82:186-195. IF2017 = 10,250;                5YIF = 10,748

4- Androdias G, Bernard E, Biotti D, Collongues N, Durand-Dubief F, Pique J, Sanchez I, Delmas C, Ninet J, Marignier R, Vukusic S. Multiple sclerosis broke my heart. Ann Neurol2017;81:754-758.              IF2017 = 10,250; 5YIF = 10,748

5- Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Seze J, Fox R, Gold R, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Hartung HP, Cree BAC. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology. 2017;89:1584-1593. IF2017 = 8,055; 5YIF = 8,716

6- Muller S, Brun S, René F, de Seze J, Loeffler JP, Jeltsch-David H. Autophagy in neuroinflammatory diseases. Autoimmun Rev. 2017;doi: 10.1016/j.autrev.2017.05.015. IF2017 = 8,745; 5YIF =7,733

 

7- Berzero G, Karantoni E, Dehais C, Ducray F, Thomas L, Picard G, Rogemond V, Candelier G, Camdessanché JP, Antoine JC, De Seze J, Liou-Schischmanoff A, Honnorat J, Delattre JY, Psimaras D. Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. J Neurol Neurosurg Psychiatry. 2017;doi: 10.1136/jnnp-2017-316904. IF2017 = 7,714;     5YIF = 6,923

 

8- Juryńczyk M, Tackley G, Kong Y, Geraldes R, Matthews L, Woodhall M, Waters P, Kuker W, Craner M, Weir A, DeLuca GC, Kremer S, Leite MI, Vincent A, Jacob A, de Seze J, Palace J. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. IF2017 = 7,714; 5YIF = 6,923

 

9- Lejri I, Grimm A, Geoffroy P, Miesch M, Eckert A, Mensah-Nyagan AG. Allopregnanolone and its analog BR 297 rescue neuronal cells from oxidative stress-induced death through bioenergetic improvement. (BBA)-Molecular Basis of Disease. 2017;1863:631-642. IF2017 = 5,108; 5YIF = 5,964

 

10- Leva G, Klein C, Benyounes J, Hallé F, Bihel F, Collongues N, De Seze JMensah-Nyagan AG, Patte-Mensah C. The translocator protein ligand XBD173 improves clinical symptoms and neuropathological markers in the SJL/J mouse model of multiple sclerosis. (BBA)-Molecular Basis of Disease2017;1863:3016-3027. IF2017 = 5,108; 5YIF = 5,964

11- Locci A, Geoffroy P, Miesch M, Mensah-Nyagan AG, Pinna G. Social Isolation in Early versus Late Adolescent Mice Is Associated with Persistent Behavioral Deficits That Can Be Improved by Neurosteroid-Based Treatment. Front Cell Neurosci2017;11:208. IF2017 = 4,300; 5YIF = 4,915

12- Roux J, Bard D, Le Pabic E, Segala C, Reis J, Ongagna JC, de Seze J, Leray E. Air pollution by particulate matter PM10 may trigger multiple sclerosis relapses. Environ Res. 2017;156:404-410.      IF2017 = 4,732; 5YIF = 4,744

13- Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP). Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler J2017;10:1377-1384. IF 2017 = 5,280; 5YIF = 4,741

 

14- Brochet B, Deloire MS, Perez P, Loock T, Baschet L, Debouverie M, Pittion S, Ouallet JC, Clavelou P, de Seze J, Collongues N, Vermersch P, Zéphir H, Castelnovo G, Labauge P, Lebrun C, Cohen M, Ruet A; PROMESS study investigators. Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. PLoS One. 2017;12:e0168834. IF 2017 = 2,766; 5YIF = 3,352

 

15- Taleb O*, Bouzobra F*, Tekin-Pala H, Meyer L, Mensah-Nyagan AG§, Patte-Mensah C§. Behavioral and electromyographic assessment of oxaliplatin-induced motor dysfunctions: evidence for a therapeutic effect of allopregnanolone. Behav Brain Res. 2017;320:440-449. *co-first authors. §Co-last authors. IF2017 = 3,713; 5YIF = 3,064

 

16- Bezine M, Debbabi M, Nury T, Ben-Khalifa R, Samadi M, Cherkaoui-Malki M, Vejux A, Raas Q, de Seze J, Moreau T, El-Ayeb M, Lizard G. Evidence of K+ homeostasis disruption in cellular dysfunction triggered by 7-ketocholesterol, 24S-hydroxycholesterol, and tetracosanoic acid (C24:0) in 158N murine oligodendrocytes. Chem Phys Lipids2017;207:135-150. IF2017 = 2,766; 5YIF = 2,650

17- Zaenker P, Favret F, Lonsdorfer E, Muff G, De Seze J, Isner-Horobeti ME. High-intensity interval training combined with resistance training improves physiological capacities, strength and quality of life in multiple sclerosis patients: a pilot study. Eur J Phys Rehabil Med2017;doi: 10.23736/S1973-9087.17.04637-8. IF2017 = 2,208; 5YIF = 2,280

18- Kintz P, Farrugia A, Ameline A, Eibel A, Raul JS. High risk of misinterpreting hair analysis results for children tested for methadone. Forensic Sci Int. 2017;280:176-180. IF2017 = 1,974; 5YIF = 2,271

29- Ameline A, Farrugia A, Raul JS, Kintz P. Retrospective demonstration of 25I-NBOMe acute poisoning using hair analysis. Curr Pharm Biotechnol. 2017;doi: 10.2174/1389201019666171129175148.         IF2017 = 1,819; 5YIF = 2,140

20- Kintz P, Ameline A, Eibel A, Geraut A, Farrugia A, Berthelon L, Raul JS. Interpretation of cannabis findings in the hair of very young children: mission impossible. Curr Pharm Biotechnol. 2017.doi: 10.2174/1389201019666171129180206. IF2017 = 1,819; 5YIF = 2,140